PFIZER INC — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Albert Bourla (CEO) and Cecile Guegan (CFO) issued standard Sarbanes-Oxley Section 302 and 906 certifications on November 3, 2026 for the fiscal quarter ended September 27, 2026. They certified that the quarterly report contains no material misstatements, that financial statements fairly present Pfizer's condition and operations, and that disclosure controls and internal controls over financial reporting are effective. No specific operational changes, transactions, or financial results are disclosed in these exhibits.
Why this rating
Routine SOX certification exhibits; standard quarterly compliance filing with no substantive operational or financial disclosures.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.